نتایج جستجو برای: prophylamin merck

تعداد نتایج: 2997  

Journal: :The Australian Journal of Hospital Pharmacy 1998

Journal: :The Journal of allergy and clinical immunology 2011
Linda Cox Harold Nelson Richard Lockey Christopher Calabria Thomas Chacko Ira Finegold Michael Nelson Richard Weber David I Bernstein Joann Blessing-Moore David A Khan David M Lang Richard A Nicklas John Oppenheimer Jay M Portnoy Christopher Randolph Diane E Schuller Sheldon L Spector Stephen Tilles Dana Wallace

Disclosure of potential conflict of interest: L. Cox is a consultant for Genentech/Novartis, Hollister-Stier, and Stallergenes; is a speaker for Novartis; has received research support from Stallergenes; is on the Board of Directors for the American Board of Allergy and Immunology; and is on the US Food and Drug Administration (FDA)’s Allergenic Product Advisory Committee. H. Nelson is a consul...

2012
Richard Stevens

Next-generation sequencing (NGS) is quickly replacing other methods for determining expression profiling of RNA as well as single-nucleotide variations within the genomes of both model organisms and human samples. At the Boston facility of Merck Research Laboratories, we concentrate on preparation and sequencing of samples where the research needs cannot be met by commercial venders. These unme...

Journal: :The Journal of infectious diseases 2000
A R Marques S C Weir G A Fahle S H Fischer

formation was published in an erratum in the February issue of the Journal [2]. This is an obvious error, because the study, funded by Merck & Co., used the Merck & Co. product RECOMBIVAX HB/H-B-VaxII. The Discussion section discussed only the use of RECOMBIVAX HB/H-B-VaxII as a 2-dose regimen. It was not our intent to suggest that the Twinrix product did not stimulate a good immunologic respon...

2011
Eli O. Meltzer

Dr Meltzer has received grant/research support from Alcon, Alexza Pharmaceuticals, Amgen, Antigen Labs, Apotex, Astellas, AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Johnson & Johnson, MAP, MEDA, Medimmune, Merck, Novartis, Proctor & Gamble, Schering-Plough, Sepracor, Teva, and UCB. He has served as a consultant/speaker for Alcon, Alexza Pharmaceuticals, Amgen, AstraZeneca, Boeh...

2014
Rajesh Krishna Matthew Rizk Valerie Schulz Jolanda Bruggencate-Broeders Ran Liu Patrick Larson Khalid Abou-Farha

Background. ISENTRESS (raltegravir, RAL) is licensed for 400 mg b.i.d. use. An investigational 1200 mg q.d. regimen for reformulated raltegravir (re-RAL) is under clinical development. This study assessed the safety and pharmacokinetics (PK) of a higher dose of re-RAL. Methods. A double-blind, multiple-dose, randomized, fully domiciled study assessed the safety and PK of 1800 mg dose of re-RAL ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید